The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
Abstract
Background Angiotensin II type 1 receptor blockers have favourable effects on haemodynamic measurements, neurohumoral activity, and left-ventricular remodelling when added to angiotensin-converting-enzyme (ACE) inhibitors in patients with chronic heart failure (CHF). We aimed to find out whether these drugs improve clinical outcome.Methods Between March, 1999, and November, 1999, we enrolled 2548 patients with New York Heart Association functional class II-IV CHF and left-ventricular ejection fraction 40% or lower, and who were being treated with ACE inhibitors. We randomly assigned patients candesartan (n=1276, target dose 32 mg once daily) or placebo (n=1272). At baseline, 55% of patients were also treated with beta blockers and 17% with spironolactone. The primary outcome of the study was the composite of cardiovascular death or hospital admission for CHF. Analysis was done by intention to treat.Findings The median follow-up was 41 months. 483 (38%) patients in the candesartan group and 538 (42%) in the placebo group experienced the primary outcome (unadjusted hazard ratio 0.85 [95% CI 0.75-0.96], p=0.011; covariate adjusted p=0.010). Candesartan reduced each of the components of the primary outcome significantly, as well as the total number of hospital admissions for CHF. The benefits of candesartan were similar in all predefined subgroups, including patients receiving baseline beta blocker treatment.Interpretation The addition of candesartan to ACE inhibitor and other treatment leads to a further clinically important reduction in relevant cardiovascular events in patients with CHF and reduced left-ventricular ejection fraction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30-40% of patients)”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [38]
In the citing paper
“In clinical trials of chronic HF patients, the prevalence of T2DM was around 30%, irrespective of HF phenotype (i.e.HFrEF and HFpEF) (Table 3).31 -48”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [38]
In the citing paper
“The highest prevalence of T2DM was seen in trials of acute HF (around 40%).”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [38]
In the citing paper
“In patients with congestive heart failure (CHF), including diabetic subgroups, ARBs have been shown to reduce major CVD outcomes (175–178), and in type 2 patients with significant nephropathy, ARBs were superior to calcium channel blockers for reducing heart failure (179–181).”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [177]
Citations
Cites
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Garg, R. (1995) · JAMA · doi:10.1001/jama.273.18.1450 · Cited by 1,993
Hunt, S. A., Baker, D. W., Chin, M. H., Cinquegrani, M. P., Feldman, A. M., Francis, G. S., Ganiats, T. G., Goldstein, S., Gregoratos, G., Jessup, M. L., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01683-7 · Cited by 1,909
Pfeffer, M. A., Swedberg, K. B., Granger, C. B., Held, P., McMurray, J. J. V., Michelson, E. L., Olofsson, B., Östergren, J., & Yusuf, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14282-1 · Cited by 1,895
Self-citationGuidelines for the diagnosis and treatment of chronic heart failure
Remme, W. J. (2001) · European Heart Journal · doi:10.1053/euhj.2001.2783 · Cited by 1,595
Flather, M. D., Yusuf, S., Køber, L., Pfeffer, M. A., Hall, A. S., Murray, G. D., Torp-Pedersen, C. T., Ball, S. G., Pogue, J. M., Moyé, L. A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02212-1 · Cited by 1,585
Self-citationCleland, J. G. F. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00823-0 · Cited by 1,553
Hunt, S. A., Baker, D. W., Chin, M. H., Cinquegrani, M. P., Feldman, A. M., Francis, G. S., Ganiats, T. G., Goldstein, S., Gregoratos, G., Jessup, M. L., et al. (2001) · Circulation · doi:10.1161/hc4901.102568 · Cited by 1,440
Effect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart Failure
Packer, M., O’Connor, C. M., Ghali, J. K., Pressler, M. L., Carson, P. E., Belkin, R. N., Miller, A. B., Neuberg, G. W., Frid, D. J., WERTHEIMER, J. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610103351504 · Cited by 1,194
Cited by
Sorted by citations
Items 301–400 of 1,001
The past, present and future of renin–angiotensin aldosterone system inhibition
Mentz, R. J., Bakris, G. L., Waeber, B., McMurray, J. J. V., Gheorghiade, M., Ruilope, L. M., Maggioni, A. P., Swedberg, K. B., Piña, I. L., Fiuzat, M., et al. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.10.007 · Cited by 121
Self-citationHudson, M., Rahme, E., Behlouli, H., Sheppard, R. J., & Pilote, L. (2007) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2007.02.001 · Cited by 117
Sarwar, C. M. S., Papadimitriou, L., Pitt, B., Piña, I. L., Zannad, F. M., Anker, S. D., Gheorghiade, M., & Butler, J. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.060 · Cited by 117
Gustafsson, F., & ARNOLD, J. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.06.023 · Cited by 118
Doppler Echocardiography Yields Dubious Estimates of Left Ventricular Diastolic Pressures
Tschöpe, C., & Paulus, W. J. (2009) · Circulation · doi:10.1161/circulationaha.109.869628 · Cited by 116
Gheorghiade, M., Patel, K., Filippatos, G. S., Anker, S. D., van Veldhuisen, D. J., Cleland, J. G. F., Metra, M., Aban, I., Greene, S. J., Adams, K. F., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft010 · Cited by 117
Self-citationUpdate on heart failure management and future directions
Choi, H., Park, M., & Youn, J. (2018) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2018.428 · Cited by 117
Rakugi, H., Enya, K., Sugiura, K., & Ikeda, Y. (2012) · Hypertension Research · doi:10.1038/hr.2012.8 · Cited by 114
Dunlay, S. M., & Roger, V. L. (2012) · Current Heart Failure Reports · doi:10.1007/s11897-012-0107-7 · Cited by 118
de Diagnóstico, G. D. T., & de Cardiología, T. D. L. I. C. C. D. L. S. E. (2005) · Revista Española de Cardiología · doi:10.1157/13078554 · Cited by 113
Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation
Abdul‐Rahim, A. H., Moreno, A. C. P., Fulton, R. L., Jhund, P. S., Latini, R., Tognoni, G., Wikstrand, J., KJEKSHUS, J. K., Lip, G. Y. H., Maggioni, A. P., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013760 · Cited by 114
Self-citationHeart failure burden and therapy
Zannad, F. M., Agrinier, N., & Alla, F. (2009) · EP Europace · doi:10.1093/europace/eup304 · Cited by 115
Clinical Characteristics and Outcomes of Young and Very Young Adults With Heart Failure
Wong, C. M., Hawkins, N. M., Jhund, P. S., MacDonald, M. R., Solomon, S. D., Granger, C. B., Yusuf, S., Pfeffer, M. A., Swedberg, K. B., Petrie, M. C., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.072 · Cited by 113
Self-citationThe renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure
Pugliese, N. R., Masi, S., & Taddei, S. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09855-5 · Cited by 117
Pathophysiological regulation of the AT1-receptor and implications for vascular disease
Waßmann, S., & Nickenig, G. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000220402.53869.72 · Cited by 112
Edner, M., Benson, L., Dahlström, U., & Lund, L. H. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv268 · Cited by 113
Izzo, J. L., & Gradman, A. H. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.06.002 · Cited by 112
Angiotensin II and Oxidative Stress in the Failing Heart
Zablocki, D., & Sadoshima, J. (2012) · Antioxidants and Redox Signaling · doi:10.1089/ars.2012.4588 · Cited by 110
Factors, fiction and endothelium‐derived hyperpolarizing factor
Sandow, S. L. (2004) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2004.04048.x · Cited by 110
Montecucco, F., Pende, A., & Mach, F. (2009) · Mediators of Inflammation · doi:10.1155/2009/752406 · Cited by 113
Inohara, T., Manandhar, P., Kosinski, A. S., Matsouaka, R., Kohsaka, S., Mentz, R. J., Thourani, V. H., Carroll, J. D., Kirtane, A. J., Bavaria, J. E., et al. (2018) · JAMA · doi:10.1001/jama.2018.18077 · Cited by 109
Haymore, B. R., Yoon, J., Mikita, C. P., Klote, M. M., & DeZee, K. J. (2008) · Annals of Allergy Asthma & Immunology · doi:10.1016/s1081-1206(10)60288-8 · Cited by 109
MANAGEMENT OF END STAGE HEART FAILURE
Friedrich, E. B., & Böhm, M. (2007) · Heart · doi:10.1136/hrt.2006.098814 · Cited by 115
Khan, N. A., Hemmelgarn, B. R., Padwal, R. S., Larochelle, P. M., Mahon, J. L., Lewanczuk, R. Z., McAlister, F. A., Rabkin, S. W., Hill, M. D., Feldman, R. D., et al. (2007) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(07)70798-5 · Cited by 109
Jujo, K., Saito, K., Ishida, I., Furuki, Y., Kim, A., Suzuki, Y., Sekiguchi, H., Yamaguchi, J., Ogawa, H., & Hagiwara, N. (2016) · ESC Heart Failure · doi:10.1002/ehf2.12088 · Cited by 107
Diabetic Nephropathy: The Proteinuria Hypothesis
Williams, M. E. (2005) · American Journal of Nephrology · doi:10.1159/000084286 · Cited by 108
Combination therapy in hypertension: An update
Kalra, S., Kalra, B., & Agrawal, N. K. (2010) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-2-44 · Cited by 111
Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future
Wintrich, J., Kindermann, I., Ukena, C., Selejan, S., Werner, C. M., Maack, C., Laufs, U., Tschöpe, C., Anker, S. D., Lam, C. S. P., et al. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01633-w · Cited by 106
2024 EACTS Guidelines on perioperative medication in adult cardiac surgery
Jeppsson, A., (Sweden), (.-C., Rocca, B., (Italy), (.-C., Hansson, E. C., (Sweden), Guðbjartsson, T., (Iceland), James, S. K., (Sweden), et al. (2024) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezae355 · Cited by 114
Hellawell, J. L., & Margulies, K. B. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00247.x · Cited by 106
Edema formation in congestive heart failure and the underlying mechanisms
Abassi, Z. A., Khoury, E. E., Karram, T., & Aronson, D. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.933215 · Cited by 122
Remme, W. J., McMurray, J. J. V., Hobbs, R. F., Solal, A. C., Lopez-Sendon, J. L., Boccanelli, A., Zannad, F. M., Rauch, B. H., Keukelaar, K., Macarie, C., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn196 · Cited by 105
Self-citationKurtz, T. W. (2005) · Acta Diabetologica · doi:10.1007/s00592-005-0176-0 · Cited by 104
Dihydropyridine Calcium Channel Antagonists in the Management of Hypertension
Epstein, B. J., Vogel, K., & Palmer, B. F. (2007) · Drugs · doi:10.2165/00003495-200767090-00005 · Cited by 104
I Diretriz Latino-Americana para o Diagnóstico e Tratamento da Cardiopatia Chagásica
Castro, I., de Andrade, J. P., de Paola, Â. A. V., Vilas‐Boas, F., de Oliveira, G. M. M., Marin‐Neto, J. A., Chagas, A. C. P., Rocha, E. A. V., de Oliveira, G. M. M., Zimerman, L. I., et al. (2011) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2011001600001 · Cited by 103
Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis
Cleland, J. G. F., Carubelli, V., Castiello, T., Yassin, A., Pellicori, P., & Antony, R. (2012) · Heart Failure Reviews · doi:10.1007/s10741-012-9306-2 · Cited by 105
Heart Failure Outcomes in Clinical Trials of Glucose-Lowering Agents in Patients with Diabetes
FITCHETT, D. H., Udell, J. A., & Inzucchi, S. E. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.633 · Cited by 102
White, H. D., Aylward, P. E., Huang, Z., Dalby, A. J., Weaver, W. D., Barvik, S., Marin‐Neto, J. A., Murín, J., Nordlander, R., van Gilst, W. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.551143 · Cited by 102
Self-citationGuía sobre el diagnóstico y tratamiento de la hipertensión arterial en España 2005
Marín, R., de la Sierra, Á., Armario, P., Campo, C., Banegas, J. R., & Gorostidi, M. (2005) · Medicina Clínica · doi:10.1157/13076402 · Cited by 106
Genetic causes of dilated cardiomyopathy
Mestroni, L., Brun, F., Spezzacatene, A., Sinagra, G., & Taylor, M. R. G. (2014) · Progress in Pediatric Cardiology · doi:10.1016/j.ppedcard.2014.10.003 · Cited by 105
Shun-Shin, M. J., Zheng, S. L., Cole, G. D., Howard, J. P., Whinnett, Z. I., & Francis, D. P. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx028 · Cited by 100
Baker, W. L., Coleman, C. I., Kluger, J., Reinhart, K. M., Talati, R., Quercia, R., Phung, O. J., & White, C. M. (2009) · Annals of Internal Medicine · doi:10.7326/0000605-200912150-00162 · Cited by 99
Evaluación y tratamiento de la hipertensión arterial en España. Documento de consenso
de la Sierra, A., Gorostidi, M., Marín, R., Redón, J., Banegas, J. R., Armario, P., Puig, J. G., Zarco, J., Llisterri, J. L., Sanchís, C., et al. (2008) · Medicina Clínica · doi:10.1157/13124015 · Cited by 98
McMurray, J. J. V., Young, J. B., Dunlap, M. E., Granger, C. B., Hainer, J. W., Michelson, E. L., Earle, S., Olofsson, B., Östergren, J., Yusuf, S., et al. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.02.028 · Cited by 98
Self-citationCongestive hepatopathy and hypoxic hepatitis in heart failure: A cardiologist's point of view
Kavoliūnienė, A., Vaitiekienė, A., & Čėsnaitė, G. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.05.003 · Cited by 97
Krum, H., Carson, P. E., Farsang, C., Maggioni, A. P., Glazer, R. D., Aknay, N., Chiang, Y., & Cohn, J. N. (2004) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2004.09.005 · Cited by 97
Böhm, M., Anker, S. D., Butler, J., Filippatos, G. S., Ferreira, J. P., Pocock, S., Mahfoud, F., Brueckmann, M., Jamal, W., Ofstad, A. P., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.049 · Cited by 96
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Greenlaw, N., Lefkowitz, M. P., Rizkala, A. R., Shi, V. C., Rouleau, J. L., Solomon, S. D., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu455 · Cited by 95
Self-citationTargeting the renin–angiotensin–aldosterone system in heart failure
Lang, C. C., & Struthers, A. D. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.196 · Cited by 97
Polhemus, D. J., Trivedi, R. K., Gao, J., Li, Z., Scarborough, A. L., Goodchild, T. T., Varner, K. J., Xia, H., Smart, F. W., Kapusta, D. R., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.056 · Cited by 94
Hyperkalemia in Real-World Patients Under Continuous Medical Care in Japan
Kashihara, N., Kohsaka, S., Kanda, E., Okami, S., & Yajima, T. (2019) · Kidney International Reports · doi:10.1016/j.ekir.2019.05.018 · Cited by 94
Angiotensin receptor blockers for heart failure
Heran, B. S., Musini, V. M., Bassett, K. L., Taylor, R. S., & Wright, J. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003040.pub2 · Cited by 105
Drugs for Left Ventricular Remodeling in Heart Failure
Frigerio, M., & Roubina, E. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.09.060 · Cited by 94
Mode of Death in Patients With Heart Failure and Reduced vs. Preserved Ejection Fraction
Hamaguchi, S., Kinugawa, S., Sobirin, M. A., Goto, D., Tsuchihashi‐Makaya, M., Yamada, S., Yokoshiki, H., & Tsutsui, H. (2012) · Circulation Journal · doi:10.1253/circj.cj-11-1355 · Cited by 94
The clinical use of angiotensin-converting enzyme inhibitors
Wong, J. S., Patel, R. A., & Kowey, P. R. (2004) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2004.04.003 · Cited by 95
Schou, M., Gustafsson, F., Videbæk, L. M., Tuxen, C., Keller, N., Handberg, J., Knudsen, A. S., Espersen, G. T., Markenvard, J., Egstrup, K., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs235 · Cited by 93
Serenelli, M., Jackson, A. M., Dewan, P., Jhund, P. S., Petrie, M. C., Rossignol, P., Campo, G. C., Pitt, B., Zannad, F. M., Ferreira, J. P., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2019.09.011 · Cited by 92
Self-citationSalehian, O., Healey, J. S., Stambler, B. S., Alnemer, K., Almerri, K., Grover, J., Bata, I. R., Mann, J. F. E., Matthew, J., Pogue, J. M., et al. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.04.062 · Cited by 92
Self-citationProtective Effects of Angiotensin II Interruption: Evidence for Antiinflammatory Actions
Dagenais, N. J., & Jamali, F. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.9.1213 · Cited by 94
Miyata, M., Kihara, T., Kubozono, T., Ikeda, Y., Shinsato, T., Izumi, T., Matsuzaki, M., Yamaguchi, T., Kasanuki, H., Daida, H., et al. (2008) · Journal of Cardiology · doi:10.1016/j.jjcc.2008.07.009 · Cited by 92
Rhythm Control in Heart Failure Patients With Atrial Fibrillation
Trulock, K. M., Narayan, S. M., & Piccini, J. P. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.06.1169 · Cited by 92
Kirchhof, P. F., Medicine, E. C. R. A. E. A. W. S. O. P., Sipido, K. R., Medicine, E. C. R. A. E. A. W. S. O. P., Cowie, M., Medicine, E. C. R. A. E. A. W. S. O. P., Eschenhagen, T., Medicine, E. C. R. A. E. A. W. S. O. P., Fox, K. A. A., Medicine, E. C. R. A. E. A. W. S. O. P., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu312 · Cited by 93
Self-citationProgression of Cardiovascular Damage: The Role of Renin–Angiotensin System Blockade
Probstfield, J. L., & O’Brien, K. D. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.10.006 · Cited by 92
Gustafsson, M., Alehagen, U., & Johansson, P. (2015) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2015.02.004 · Cited by 94
Yeh, J. M., Nohria, A., & Diller, L. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2266 · Cited by 89
Pathogenesis of Chronic Cardiorenal Syndrome: Is There a Role for Oxidative Stress?
Rubattu, S., Mennuni, S., Testa, M., Mennuni, M., Pierelli, G., Pagliaro, B., Gabriele, E., Coluccia, R., Autore, C., & Volpe, M. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141123011 · Cited by 89
Diabetes Mellitus and Heart Failure: Epidemiology, Mechanisms, and Pharmacotherapy
Masoudi, F. A., & Inzucchi, S. E. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.013 · Cited by 89
Brown, M. J. (2007) · Heart · doi:10.1136/hrt.2006.107706 · Cited by 89
Tai, C., Gan, T., Zou, L., Sun, Y., Zhang, Y., Chen, W., Li, J., Zhang, J., Xu, Y., Lu, H.-H., et al. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0686-z · Cited by 88
Medical Therapies for Heart Failure With Preserved Ejection Fraction
Kjeldsen, S. E., von Lueder, T. G., Smiseth, O. A., Wachtell, K., Mistry, N., Westheim, A. S., Hopper, I., Julius, S., Pitt, B., Reid, C. M., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.14057 · Cited by 91
Kristensen, S. L., Køber, L., Jhund, P. S., Solomon, S. D., KJEKSHUS, J. K., McKelvie, R. S., Zile, M. R., Granger, C. B., Wikstrand, J., Michel Komajda, N., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.012284 · Cited by 88
Self-citationRaebel, M. A., McClure, D. L., Simon, S. R., Chan, K. A., Feldstein, A. C., Andrade, S. E., Lafata, J. E., Roblin, D. W., Davis, R. L., Gunter, M. J., et al. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1217 · Cited by 88
Angiotensin receptor blockers and risk of myocardial infarction: systematic review
McDonald, M. A., Simpson, S. H., Ezekowitz, J. A., Gyenes, G., & Tsuyuki, R. T. (2005) · BMJ · doi:10.1136/bmj.38595.518542.3a · Cited by 87
Medication Dosing for Heart Failure with Reduced Ejection Fraction — Opportunities and Challenges
Marti, C. N., Fonarow, G. C., Anker, S. D., Yancy, C. W., Vaduganathan, M., Greene, S. J., Ahmed, A., Januzzi, J. L., Gheorghiade, M., Filippatos, G. S., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1351 · Cited by 87
Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure
Borow, K. M., Yaroshinsky, A., Greenberg, B., & Perin, E. C. (2019) · Circulation Research · doi:10.1161/circresaha.119.314951 · Cited by 89
Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection
Ruilope, L. M., Rosei, E. A., Bakris, G. L., Mancia, G., Poulter, N. R., Taddei, S., Unger, T., Volpe, M., Waeber, B., & Zannad, F. M. (2005) · Blood Pressure · doi:10.1080/08037050500230227 · Cited by 85
RAAS Inhibitors and Cardiovascular Protection in Large Scale Trials
von Lueder, T. G., & Krum, H. (2012) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-012-6424-y · Cited by 85
Raizada, V., SKIPPER, B. J., Luo, W., & Griffith, J. K. (2007) · Journal of Investigative Medicine · doi:10.2310/6650.2007.00020 · Cited by 84
Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties
Deppe, S., Böger, R. H., Weiß, J., & Benndorf, R. A. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.494597 · Cited by 84
Jhund, P. S., Claggett, B. L., Packer, M., Zile, M. R., Voors, A. A., Pieske, B. M., Lefkowitz, M. P., Shi, V. C., Bransford, T. L., McMurray, J. J. V., et al. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.76 · Cited by 83
Self-citationAngiotensin II Receptor Blockers and Risk of Cancer in Patients With Systemic Hypertension
Huang, C., Chan, W., Chen, Y., Chen, T., Lin, S., Chen, J., & Leu, H. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.11.026 · Cited by 84
Castagno, D., Petrie, M. C., Claggett, B. L., & McMurray, J. J. V. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs004 · Cited by 83
Self-citationEffects of Candesartan on Cardiovascular Outcomes in Japanese Hypertensive Patients
Suzuki, H., & Kanno, Y. (2005) · Hypertension Research · doi:10.1291/hypres.28.307 · Cited by 84
Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials
Verdecchia, P., Gentile, G., Angeli, F., Mazzotta, G., Mancia, G., & Reboldi, G. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e328338e2bb · Cited by 87
Treatment for chronic heart failure in the elderly: current practice and problems
Abete, P., Testa, G., Della‐Morte, D., Gargiulo, G., Galizia, G., de Santis, D., Magliocca, A., Basile, C., & Cacciatore, F. (2012) · Heart Failure Reviews · doi:10.1007/s10741-012-9363-6 · Cited by 82
McMurray, J. J. V. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfr093 · Cited by 82
Self-citationMyofibroblasts in the Infarct Area: Concepts and Challenges
Daskalopoulos, E. P., Janssen, B. J., & Blankesteijn, W. M. (2012) · Microscopy and Microanalysis · doi:10.1017/s143192761101227x · Cited by 82
D’Amario, D., Rodolico, D., Rosano, G. M. C., Dahlström, U., Crea, F., Lund, L. H., & Savarese, G. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2477 · Cited by 81
Caldeira, D., David, C., & Sampaio, C. (2012) · American Journal of Cardiovascular Drugs · doi:10.1007/bf03261835 · Cited by 81
An update on non-peptide angiotensin receptor antagonists and related RAAS modulators
Aulakh, G. K., Sodhi, R. K., & Singh, M. (2007) · Life Sciences · doi:10.1016/j.lfs.2007.06.007 · Cited by 83
Koka, V., Wang, W., Huang, X. R., Kim‐Mitsuyama, S., Truong, L. D., & Lan, H. Y. (2006) · Circulation · doi:10.1161/circulationaha.105.575589 · Cited by 81
Exercise Training in Congestive Heart Failure: Risks and Benefits
Keteyian, S. J. (2011) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2011.02.005 · Cited by 80
Cardiorenal Syndrome in Critical Care: The Acute Cardiorenal and Renocardiac Syndromes
Cruz, D. N. (2012) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2012.10.005 · Cited by 81
Treatment of hypertension in patients with coronary artery disease
Rosendorff, C., Lackland, D. T., Allison, M., Aronow, W. S., Black, H. R., Blumenthal, R. S., Cannon, C. P., de Lemos, J. A., Elliott, W. J., Findeiss, L., et al. (2015) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2015.03.002 · Cited by 79
Guías de práctica clínica para el tratamiento de la hipertensión arterial 2007
(ESH), G. D. T. P. E. T. D. L. H. A. D. L. S. E. D. H., & de Cardiología, D. L. S. E. (2007) · Revista Española de Cardiología · doi:10.1157/13109650 · Cited by 79
Management of acute decompensated heart failure
Allen, L. A., & O'Connor, C. M. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.051620 · Cited by 80
Athyros, V. G., Mikhailidis, D. P., Kakafika, A. I., Τζιόμαλος, Κ., & Karagiannis, A. I. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.5.529 · Cited by 80
Zannad, F. M., Stough, W. G., Regnault, V., Gheorghiade, M., Deliargyris, E., Gibson, C. M., Agewall, S., Berkowitz, S. D., Burton, P. B. J., Calvo, G., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.12.018 · Cited by 79
Medical therapy for chronic heart failure
Krum, H., & Teerlink, J. R. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61038-6 · Cited by 82
Mazurek, J. A., & Jessup, M. L. (2015) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2015.08.001 · Cited by 78
Metadata
- Authors
- McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A.
- Affiliations
- University of Glasgow (GB)
- Karolinska University Hospital (SE)
- Sahlgrenska University Hospital (SE)
- Duke Medical Center (US)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (United States) (US)
- Hamilton Health Sciences (CA)
- Brigham and Women's Hospital (US)
- Corresponding author
- McMurray, John JV
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2003-09
- Volume
- 362
- Issue
- 9386
- Pages
- 767-771
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2098780362
- Cited by
- 2,604
- References
- 38
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 46 · 2023: 52 · 2022: 58 · 2021: 60 · 2020: 98 · 2019: 82 · 2018: 66 · 2017: 103 · 2016: 108 · 2015: 118 · 2014: 122 · 2013: 126 · 2012: 153
- FWCI
- 122.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- candesartan, chronic heart failure, reduced left ventricular ejection fraction, angiotensin receptor blockers, ACE inhibitors, combination therapy, cardiovascular mortality, beta-blockers, spironolactone
- MeSH terms
- Adolescent, Adult, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Benzimidazoles, Biphenyl Compounds, Cardiac Output, Low, Cardiovascular Diseases, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Placebos, Tetrazoles, Comorbidity, Treatment Outcome, Ventricular Dysfunction, Left, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
